Regenxbio said its experimental gene therapy for Duchenne muscular dystrophy succeeded in a trial, paving the way for a submission to the FDA.
Regenxbio’s headquarters in Rockville, Md.Regenxbio
By Adam Feuerstein and Jason Mast
May 14, 2026
Adam Feuerstein
adam.feuerstein@statnews.com
Diamantas takes the reins, Regenxbio stakes claim in Duchenne gene therapy, and more biotech news from The Readout
A next-gen Duchenne therapy from Entrada Therapeutics fell short in an early study, as a number of companies race to make…
Latus Bio raised $42 million as it prepares to seek FDA approval to start a clinical trial for its gene therapy for Huntington's…
The drug, which was designed to treat Duchenne muscular dystrophy, has been linked to the deaths of two teenage boys.
A Cytokinetics heart disease drug — already approved in one indication — succeeded in another Phase 3 trial, a potential boost…
A Duchenne therapy lawsuit, FDA Commissioner Marty Makary’s White House troubles, and other news from The Readout
